Picture 1 of 1
Gallery
Picture 1 of 1
Have one to sell?
INTEGRATION OF PHARMACEUTICAL DISCOVERY AND DEVELOPMENT: CASE HISTORIES, 1998
US $29.00
ApproximatelyS$ 37.65
Condition:
“CONDITION: VERY GOOD. Unread copy with stamps on endpaper and top edge from business library.”
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Shipping:
US $6.72 (approx S$ 8.73) USPS Media MailTM.
Located in: Saint Paul, Minnesota, United States
Delivery:
Estimated between Tue, 28 Oct and Sat, 1 Nov to 94104
Returns:
No returns accepted.
Coverage:
Read item description or contact seller for details. See all detailsSee all details on coverage
(Not eligible for eBay purchase protection programmes)
Seller assumes all responsibility for this listing.
eBay item number:333862302992
Item specifics
- Condition
- Very Good
- Seller Notes
- “CONDITION: VERY GOOD. Unread copy with stamps on endpaper and top edge from business library.”
- ISBN
- 9780306457432
About this product
Product Identifiers
Publisher
Springer
ISBN-10
0306457431
ISBN-13
9780306457432
eBay Product ID (ePID)
936734
Product Key Features
Number of Pages
Xxix, 610 Pages
Publication Name
Integration of Pharmaceutical Discovery and Development : Case Histories
Language
English
Publication Year
1998
Subject
Life Sciences / Biochemistry, Life Sciences / Anatomy & Physiology (See Also Life Sciences / Human Anatomy & Physiology), Pharmacology
Type
Textbook
Subject Area
Science, Medical
Series
Pharmaceutical Biotechnology Ser.
Format
Hardcover
Dimensions
Item Weight
39.8 Oz
Item Length
9 in
Item Width
6 in
Additional Product Features
Intended Audience
Scholarly & Professional
LCCN
98-027185
Dewey Edition
22
Series Volume Number
11
Number of Volumes
1 vol.
Illustrated
Yes
Dewey Decimal
615.19
Table Of Content
Renin Inhibitors.- The Discovery and Development of Angiotensin II Antagonists.- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor.- Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707.- Endothelin Receptor Antagonists.- LHRH Antagonists.- LHRH Agonists.- Discovery and Development of Somatostatin Agonists.- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors.- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development.- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule.- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate.- Famciclovir.- The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics.- Hematoregulators.- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase.- Discovery of a Potent and Selective ?1A Antagonist.- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2.- The Anxieties of Drug Discovery and Development.- CI-1015.- Orally Active Nonpeptide CCK-A Agonists.- Orally Active Growth Hormone Secretagogues.- Dorzolamide, a 40-Year Wait.- Discovery and Development of Novel Melanogenic Drugs.
Synopsis
In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g., high affinity and specificity for the target receptor), pharmaceutical (e. g., solubility and chemical stability), bioph- maceutical (e. g., cell membrane permeability), and metabolic/pharmacokinetic (e. g., metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g., medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g., analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred., In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.
LC Classification Number
QP1-981
Item description from the seller
Seller feedback (697)
- d***h (775)- Feedback left by buyer.Past 6 monthsVerified purchaseShipped promptly and packed to preserve the brand new condition of the item as described. A good price for a great HTF OOP CD collection.
- e***i (113)- Feedback left by buyer.Past 6 monthsVerified purchaseReceived as advertised. Thanks.Blue Toyo T-360 Small Steel Tool Box, 15”L x 8.75”W x 3.75”H (#335889801901)
- r***1 (144)- Feedback left by buyer.Past 6 monthsVerified purchasegood serviceOMEGA Level Switch LV-612P PVC Cable 15-ft, Rectangular Design (#335956718037)